Varex Imaging Corporation (NASDAQ: VREX) has piqued investor curiosity with a significant potential upside of 41.43%, according to the latest analyst ratings. As a prominent player in the Healthcare sector, specifically within the Medical Devices industry, Varex Imaging is renowned for its innovative X-ray imaging components that cater to both medical and industrial applications.
With a current market capitalization of $545.37 million, Varex Imaging’s stock is trading at $13.01, demonstrating a modest price change of 0.01% recently. The stock has experienced a volatile 52-week range, oscillating between $6.88 and $14.36, highlighting the dynamic market conditions it operates within.
Investors may note that while the company’s trailing P/E ratio remains undefined, its forward P/E ratio stands at 12.75, indicating potential earnings growth in the upcoming financial periods. Despite the absence of specific PEG, Price/Book, and Price/Sales ratios, the forward-looking valuation metrics suggest room for optimism.
Performance metrics reveal a revenue growth rate of 4.90%, although the company faces challenges in profitability, with a reported EPS of -1.64 and a return on equity of -12.90%. The negative free cash flow of approximately $15.69 million further underscores the operational hurdles Varex Imaging must navigate.
The company’s dividend yield is currently non-existent, reflecting a payout ratio of 0.00%. This indicates that the firm is likely reinvesting earnings into the business rather than distributing them to shareholders, aligning with its growth-oriented strategy.
Analyst sentiment appears favorable, with four buy ratings and one hold rating, and no sell ratings. This positive outlook is supported by a target price range of $16.00 to $22.00, with an average target of $18.40. The substantial potential upside of over 41% offers an attractive prospect for investors seeking growth opportunities in the medical devices sector.
Technical indicators provide additional insight into the stock’s performance. The 50-day moving average of $13.30 and the 200-day moving average of $10.98 suggest a recent upward trend, though the relative strength index (RSI) of 39.11 indicates a stock that is neither overbought nor oversold. The MACD of -0.10, slightly below the signal line of 0.01, may prompt cautious optimism among technical analysts.
Varex Imaging’s extensive product portfolio spans a range of applications, from CT and mammography in the medical segment to non-intrusive cargo inspection systems in the industrial segment. The company’s global operations, spanning continents from North America to Australia, reinforce its diversified market presence and potential for growth.
Incorporated in 2016 and headquartered in Salt Lake City, Utah, Varex Imaging continues to leverage its expertise in X-ray imaging components to address evolving market demands. Investors considering Varex Imaging should weigh the company’s growth potential against its current financial challenges, recognizing the significant upside potential that has captured analyst and investor attention alike.
